Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE).
This study is an open-label, uncontrolled study design to evaluate the longer-term safety profile as well as durability of response of administration of a single dose level of CC-93538.
Bristol Myers Squibb announced that the FDA has accepted its New Drug Application (NDA) for CC 486, an investigational oral hypomethylating agent, for the maintenance treatment of adult patients with acute myeloid leukemia (AML),
Bristol-Myers Squibb Company announced clinical results from the QUAZAR AML-001 study, evaluating investigational agent CC 486 as maintenance therapy in...
This study will evaluate the effects of an experimental (being tested) study drug called apremilast.
Vertex Pharmaceuticals will initiate a Phase IIIb study called CONCISE that will evaluate the potential for treatment with Incivek (telaprevir)...
Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Applications (MAA) for both idecabtagene vicleucel (ide-cel, bb2121) and CC 486.
Celgene Corporation announced top-line results from the international phase III, randomized, double-blind, placebo-controlled study, QUAZAR AML-001 . The study evaluated...
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.
The cerebral cortex (CC) has long been discussed as a crucial element of its complex mechanism. The present review considers the state of the art of experimental evidence on the involvement of CC in migraine.